title: Long-term sequelae of therapy for childhood acute lymphoblastic leukaemia.
abstract: Childhood ALL has provided the model for basic therapeutic principles in the past and now provides the model for late effects studies. Common threads which run throughout the literature in this area of clinical research are the importance of young age with increased vulnerability to long-term treatment induced sequelae and the relatively large contribution of radiation as compared with chemotherapy in the pathogenesis of adverse sequelae. Previous retrospective studies of long-term childhood ALL survivors focused on neuropsychologic changes and anatomic changes in the CNS after cranial irradiation. More recent retrospective studies have made the following new observations: (i) the high frequency of significant short adult stature in those less than 6 years of age at diagnosis who received 24 Gy cranial irradiation; (ii) actuarial risk of 2.5% of developing a second malignancy with approximately one-half of secondary malignancies occurring in the CNS in children 5 years of age or less who received cranial irradiation; (iii) the association of secondary ANLL with epipodophyllo-toxin use, and (iv) delayed cardiac toxicity despite anthracycline dosage reduction. Current therapy regimens, especially in high-risk patients, are both more successful and more intensive than those used in the past. While it will be another decade before many of the long-term sequelae begin to emerge, one can anticipate, based on current experience, some of the problems that will occur.
authors: Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.
authors: J
authors: J
authors: Ochs
authors: R
authors: R
authors: Mulhern
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy / Q000009:adverse effects; D016371:Cranial Irradiation / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006130:Growth Disorders / Q000453:epidemiology / Q000209:etiology*; D006331:Heart Diseases / Q000209:etiology; D006801:Humans; D007223:Infant; D007246:Infertility / Q000209:etiology; D017254:Leukemic Infiltration / Q000628:therapy; D008297:Male; D008578:Meninges / Q000473:pathology; D001523:Mental Disorders / Q000453:epidemiology / Q000209:etiology; D009381:Neoplasms, Radiation-Induced / Q000453:epidemiology / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000453:epidemiology / Q000209:etiology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000473:pathology / Q000628:therapy*; D011832:Radiation Injuries / Q000453:epidemiology / Q000209:etiology; D016896:Treatment Outcome